Vident Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vident Advisory's ALNY Position: Q2 2026 in Review

Vident Advisory reduced its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, selling an estimated $283K and leaving 5,518 shares worth $1.66M. The position accounts for 0.01% of the portfolio, ranked #752.

Vident Advisory first reported a position in ALNY in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.39M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

• Vident Advisory held 5,518 shares of Alnylam Pharmaceuticals worth $1.66M as of Q2 2026.
• Vident Advisory sold 939 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $283K.
• Alnylam Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #752 holding.
• Vident Advisory first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
• Vident Advisory's Alnylam Pharmaceuticals position peaked at $2.39M in Q3 2025.
• 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.